Company*
(Country; Symbol) 		Company Type/Product Area Terms/Details (Date)
Cell Genesys Inc. (CEGE) GBP IP LLC (an affiliate of GBP Capital) Agreement under which Cell Genesys will sell its lentiviral gene delivery technology to GBP IP for $12M GBP gains all the intellectual property and previously established licensing agreements relating to the technology, and Cell Genesys will retain rights to use the technology for research and development purposes (12/20)
CV Therapeutics Inc. (CVTX) Medlogics Device Corp.* Licensing agreement for CV's biopolymer stent-coating technology to develop a drug eluting stent Financial terms were not disclosed, but CV received Medlogics' stock and is entitled to development milestone payments, royalties and other potential payments on future sales of any product incorporating the technology (2/5)
Forticell Bioscience Inc. (OTC BB:FORB) CJ CheilJedang*(South Korea) Material transfer and technology evaluation deal giving CJ exclusive rights for a limited time to use its Fibrin MicroBeads technology for the extraction and expansion of mesenchymal-type stem cells from human umbilical cord blood If the research is successful, both companies will share new intellectual property and can negotiate a subsequent licensing and product development agreement (1/14)
Regenetech Inc.* Korea Stem Cell Bank Co.* (Korea) License agreement covering South Korea for Regenetech's stem cell expansion technology Financial terms were not disclosed (1/14)
Notes:

* Private companies are indicated with an asterisk.

Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market.

OTC BB = Over-the-Counter Bulletin Board.